Wedding is Off! Tougher Tax Inversion Laws Sees Pfizer Dump $160 Billion Allergan Deal at the Altar

SUGAR LAND--April 8, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Thanks to Uncle Sam in the form of the U.S. Treasury and more stringent tax inversion regulations, pharmaceutical giant Pfizer Incorporated's (NYSE:PFE) (New York, New York) much ballyhooed $160 billion merger agreement with Dublin, Ireland-based Allergan (NYSE:AGN) has been called off. On April 4, the agency issued new rules to curb tax inversions by U.S. companies, with even President Barack Obama weighing in, claiming the practice to be "one of the most insidious tax loopholes out there." Within this article: Describes the failed merger deal between Pfizer and Allergan.